XELJANZ® (tofacitinib citrate) induction therapy* achieved rapid† induction of efficacy1,2
A significantly greater proportion of patients taking XELJANZ® (tofacitinib citrate) 10 mg BID achieved treatment end points versus placebo at Week 8 across multiple efficacy parameters1,2
Pooled Central Read Data From OCTAVE 1 and OCTAVE 2 Induction Studies1,2
Adapted from Sandborn WJ, et al. 2017.
*Two randomised, multicentre, double-blind, placebo-controlled Phase 3 studies of patients with moderate to severe UC who received XELJANZ® (tofacitinib citrate) 10 mg BID or placebo for 8 weeks.1
†Rapid induction as early as Week 2 in OCTAVE 1 and OCTAVE 2 studies.
‡Remission was stringently defined as a total Mayo score of ≤2, with no individual subscore of >1 and a rectal bleeding subscore of 0.1.
§Improvement of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).
IIClinical response was defined as a decrease from baseline in the Mayo score of ≥3 points and ≥30%, with an accompanying decrease in the subscore for rectal bleeding of ≥1 point or absolute subscore for rectal bleeding of 0 or 1.1 The recommended dose is 10 mg given orally BID for induction for 8 weeks.3 The recommended dose for the maintenance treatment is XELJANZ® (tofacitinib citrate) 5 mg given orally BID.
BID, twice daily; OCTAVE, Operationally Critical Threat, Asset and Vulnerability Evaluation; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.